The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

TNF Pharmaceuticals has a beta of 2.32 ... which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper ...

JERSEY CITY, NJ, USA I March 12, 2025 I Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® ...

9 Anti-TNF antibodies, such as infliximab and adalimumab, neutralize the biological activity of TNF by binding with high affinity to the soluble and transmembrane forms of TNF. Biological ...

The interplay between cortisol, inflammation, and disease underscores the need for effective stress management to enhance ...

Discover how peptides are transforming medical treatments, metabolic conditions and more with fewer side effects than ...

The report covers 2024 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene & cell therapy ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash ...

A significant percentage of patients with RA and ANCA positivity were also diagnosed with AAV, with GPA being the most common subtype.